Cargando…
LEAP-2: An Emerging Endogenous Ghrelin Receptor Antagonist in the Pathophysiology of Obesity
Liver-expressed antimicrobial peptide 2 (LEAP-2), originally described as an antimicrobial peptide, has recently been recognized as an endogenous blocker of growth hormone secretagogue receptor 1a (GHS-R1a). GHS-R1a, also known as ghrelin receptor, is a G protein-coupled receptor (GPCR) widely distr...
Autores principales: | Lu, Xuehan, Huang, Lili, Huang, Zhengxiang, Feng, Dandan, Clark, Richard J., Chen, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428150/ https://www.ncbi.nlm.nih.gov/pubmed/34512549 http://dx.doi.org/10.3389/fendo.2021.717544 |
Ejemplares similares
-
Beta-Hydroxybutyrate Suppresses Hepatic Production of the Ghrelin Receptor Antagonist LEAP2
por: Holm, Stephanie, et al.
Publicado: (2022) -
Ghrelin and ghrelin receptor modulation of psychostimulant action
por: Wellman, Paul J., et al.
Publicado: (2013) -
“A LEAP 2 conclusions? Targeting the ghrelin system to treat obesity and diabetes”
por: Gupta, Deepali, et al.
Publicado: (2020) -
PMON253 The Ghrelin/Leap-2 ratio might be associated with physiologic changes in maternal weight during different stages of pregnancy
por: Buell-Acosta, Julieth Daniela, et al.
Publicado: (2022) -
Ghrelin Receptors in Non-Mammalian Vertebrates
por: Kaiya, Hiroyuki, et al.
Publicado: (2013)